HELXvsXBIETF Comparison
VS
Franklin Genomic Advancements ETF (HELX) belongs to the BioTech & Genomics segment. State Street SPDR S&P Biotech ETF (XBI) is part of the US Health Care segment. HELX's top 3 sector exposures are Healthcare, Non-Energy Materials and Technology. In contrast, XBI's top sector exposures are Healthcare and Finance. HELX is more expensive with a Total Expense Ratio (TER) of 0.5%, versus 0.35% for XBI. HELX is up 26.78% year-to-date (YTD) with +$8M in YTD flows. XBI performs better with 29.51% YTD performance, and +$701M in YTD flows. Run a side-by-side ETF comparison of HELX and XBI below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
HELX vs XBI performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 10/29/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | HELX XBI | +3.65%+0.64% | +18.42%+6.63% | +26.78%+29.51% | +34.48%+42.76% | +81.47%+143.47% | -13.69%+27.30% |
| Flows | HELX XBI | +$2M+$321M | +$2M+$457M | +$8M+$701M | +$8M+$1.13B | +$17M-$177M | +$8M+$1.66B |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | HELX XBI | +27.48%+30.80% | +24.10%+29.02% | +21.93%+28.38% | +23.67%+33.05% |
| Max drawdown | HELX XBI | -8.93%-14.89% | -17.89%-14.89% | -29.16%-32.94% | -55.27%-53.28% |
| Max drawdown duration | HELX XBI | 22d71d | 206d71d | 458d331d | 1822d1622d |
Trading data
HELX | XBI | |
Last sale 10/30/2026 at 1:30 PM | $45.25 | $155.98 |
| Previous close 10/29/2026 | $46.01 | $157.79 |
| Consolidated volume 10/29/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of September 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
HELX
is actively managed and doesn’t replicate an indexHELX | XBI | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 10/30/2026 at 1:30 PM
Live
Closed
HELX | XBI | |
|---|---|---|
| Last price | $45.25 | $155.98 |
| 1D performance | -1.65% | -1.15% |
| AuM | $36.80 M | $10.76 B |
| E/R | 0.5% | 0.35% |
Characteristics
HELX | XBI | |
|---|---|---|
| Management strategy | Active | Passive |
| Provider | Franklin Templeton | State Street Investment Management |
| Benchmark | - | S&P Biotechnology Select Industry Index |
| N° of holdings | 66 | 159 |
| Asset class | - | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | February 25, 2020 | January 31, 2006 |
| ESG | No | No |
Advertisement
Exposure
Countries
HELX
USA
90.13%
Other
9.87%
XBI
USA
95.32%
Other
4.68%
Sectors
HELX
Healthcare
97.01%
Other
2.99%
XBI
Healthcare
99.16%
Other
0.84%
Advertisement
Diversification
HELX
Total weight of top 15 holdings out of 15
61.42%
XBI
Total weight of top 15 holdings out of 15
24.01%
Top 15 holdings
Data as of September 30, 2026
HELX
Natera, Inc.
10.25%
Guardant Health, Inc.
9.72%
Krystal Biotech, Inc.
5.32%
Twist Bioscience Corp.
5.01%
Adaptive Biotechnologies Corp.
4.95%
Ligand Pharmaceuticals, Inc.
4.33%
BridgeBio Pharma, Inc.
2.79%
Travere Therapeutics, Inc.
2.72%
Medpace Holdings, Inc.
2.64%
Vertex Pharmaceuticals, Inc.
2.62%
Corteva, Inc.
2.33%
Eli Lilly & Co.
2.25%
Tempus AI, Inc.
2.25%
United Therapeutics Corp.
2.20%
Repligen Corp.
2.04%
XBI
Twist Bioscience Corp.
2.21%
Moderna, Inc.
2.04%
Natera, Inc.
1.80%
Iovance Biotherapeutics, Inc.
1.62%
Amgen, Inc.
1.55%
Biogen, Inc.
1.54%
United Therapeutics Corp.
1.54%
AbbVie, Inc.
1.50%
Halozyme Therapeutics, Inc.
1.48%
Spyre Therapeutics, Inc.
1.47%
Gilead Sciences, Inc.
1.47%
TG Therapeutics, Inc.
1.47%
CRISPR Therapeutics AG
1.46%
Vertex Pharmaceuticals, Inc.
1.44%
Exelixis, Inc.
1.44%
Frequently asked questions about HELX and XBI
How have the HELX and XBI ETFs performed in 2026?
As of October 29, 2026, HELX is up 26.78% year-to-date (YTD), while XBI has returned 29.51%. That puts XBI better performer ahead so far this year.
Which ETF is attracting more investor money: HELX or XBI?
Year-to-date, the HELX ETF saw +$8M in flows, compared to +$701M for XBI.
Which ETF is more volatile: HELX or XBI?
Over the past year, HELX had a volatility of 24.1%, while XBI experienced 29.02%.
Which ETF is bigger: HELX or XBI?
As of October 29, 2026, HELX holds $36.80 M in assets under management (AUM), while XBI manages $10.76 B.
What sectors do the HELX and XBI ETFs invest in?
HELX leans toward sectors like Healthcare. Meanwhile, XBI focuses on Healthcare.
What are the top holdings of the HELX ETF and XBI ETF?
HELX top holdings include Natera, Inc., Guardant Health, Inc. and Krystal Biotech, Inc.. XBI holds in its top three: Twist Bioscience Corp., Moderna, Inc. and Natera, Inc..
Which ETF is more diversified: HELX or XBI?
HELX holds 66 securities with 61.42% of its assets in the top 15. XBI has 162 securities and a top 15 weight of 24.01%.
Advertisement
Latest news about HELX & XBI
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
XBI
Are Biotechnology ETFs In the Midst of a Comeback?
August 20, 2025
XBI
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
XBI
Biotech ETFs – Investing in Health Innovation
July 21, 2022
XBI
Advertisement
Advertisement
